Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of zilucoplan in immune-mediated necrotizing myopathy
NL-OMON48482Phase 2Active, not recruiting
- Sponsor
- PRA Health Sciences
- Start
- Sep 2020
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zilucoplan in immune-mediated necrotizing myopathy (IMNM), sponsored by PRA Health Sciences. Primary endpoint: Percent change from baseline to Week 8 in creatine kinase levels. Started Sep 2020; status: active, not recruiting.
02
Drugs
zilucoplan
03
Conditions
immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on NL-OMON48482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48482.